NEW YORK, October 18, 2016 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com takes a closer look at four Biotech equities, namely: Biogen Inc. (NASDAQ: BIIB), Juno Therapeutics Inc. (NASDAQ: JUNO), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), and ProNAi Therapeutics Inc. (NASDAQ: DNAI). According to IBISWorld's May 2016 market research report, the global biotechnology industry's contribution to the overall global economy is expected to grow 3.5% per year on average during the ten years to 2021 - slightly higher than the annualized global GDP growth of 2.7% over the same period. Register now and get full and free access to our downloadable research reports on these stocks at:
Shares in Cambridge, Massachusetts headquartered Biogen Inc. ended Monday's session at $291.67, rising 0.40%. The stock recorded a trading volume of 1.21 million shares. The Company's shares have gained 12.26% in the previous three months. The stock is trading 5.55% above its 200-day moving average. Moreover, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders, have a Relative Strength Index (RSI) of 35.25.
On October 8th, 2016, new data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), were presented by Biogen and Ionis Pharmaceuticals at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase 3 ENDEAR study in infantile-onset, encouraging preliminary results from NURTURE, a Phase 2 open-label study in pre-symptomatic infants, and a recent analysis of the ongoing Phase 2 open-label study in patients with later-onset SMA. Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of nusinersen. Access our complete research report on BIIB for free at:
Seattle, Washington headquartered Juno Therapeutics Inc.'s stock saw a drop of 2.93%, closing the day at $27.17 with a total trading volume of 926,642 shares. Shares of the Company, which engages in developing cell-based cancer immunotherapies, are trading 11.18% below their 50-day moving average. The stock has an RSI of 38.42. The complimentary research report on JUNO can be downloaded at:
On Monday, shares in Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc. recorded a trading volume of 498,012 shares, and ended the day 1.33% lower at $366.73. The stock is trading below its 200-day moving average by 8.17%. Shares of the Company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 31.32.
On October 17th, 2016, Regeneron Pharmaceuticals and Teva Pharmaceutical Industries Ltd. provided an update on fasinumab. The U.S. FDA has placed the Phase 2b study in chronic low back pain on clinical hold and requested an amendment of the study protocol after observing a case of adjudicated arthropathy in a patient receiving high dose fasinumab who had advanced osteoarthritis at study entry. As a result of the FDA's decision, Regeneron completed an unplanned interim review of results and has stopped dosing in the study. The unplanned analysis showed clear evidence of efficacy with improvement in pain scores in all fasinumab groups compared to placebo at the 8- and 12-week time points. Based on these results, Regeneron and Teva plan to design a pivotal Phase 3 study in chronic low back pain that excludes patients with advanced osteoarthritis. The companies plan to submit a pivotal program plan for review with the FDA and other health authorities. Register for free on Stock-Callers.com and get access to the latest PDF format report on REGN at:
Vancouver, Canada headquartered ProNAi Therapeutics Inc.'s stock declined 2.78%, finishing yesterday's session at $1.75 and with a total trading volume of 738,881 shares. Shares of the Company, which develops and commercializes drugs based on its DNA interference technology platform for patients with cancer and hematological malignancies, are trading below their 50-day moving average by 6.54%. The stock has an RSI of 39.49.
On September 27th, 2016, ProNAi Therapeutics announced that it has obtained an exclusive license from CRT Pioneer Fund L.P. for worldwide rights to develop and commercialize PNT737, a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1. Under the terms of the agreement, ProNAi will pay CRT Pioneer Fund an upfront payment of US$7.0 million. ProNAi will take on sponsorship and management of the clinical development of the agent from Cancer Research UK's Centre for Drug Development and pay a fee of up to $2.0 million upon the successful transfer of the two ongoing Phase 1 clinical trials to the Company. Additional payments in the aggregate amount of up to US$319.5 million may become payable upon achievement of certain development, regulatory, and commercial milestones. Download your free research report on DNAI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA